Alzheimer’s disease biological PET staging using plasma p217+tau
In addition to accurately screening for A+ individuals, plasma p217+tau is useful for identifying a combined Intermediate/Advanced stage AD cohort or pre-screening to reduce the tau-PET required to identify Advanced stage AD individuals.
Authors
- Vincent Doré (ORCID: https://orcid.org/0000-0002-8051-0558)
- Kun Huang (ORCID: https://orcid.org/0000-0002-0808-2325)
- James D. Doecke (ORCID: https://orcid.org/0000-0003-2863-0293)
- Christopher C. Rowe (ORCID: https://orcid.org/0000-0003-3910-2453)
- Jürgen Fripp
- Pierrick Bourgeat (ORCID: https://orcid.org/0000-0002-2605-4766)
- Azadeh Feizpour
- Colin L. Masters (ORCID: https://orcid.org/0000-0003-3072-7940)
- Victor L. Villemagne (ORCID: https://orcid.org/0000-0002-5832-9875)
- Gallen Triana‐Baltzer (ORCID: https://orcid.org/0000-0003-0612-1236)
- Natasha Krishnadas (ORCID: https://orcid.org/0000-0002-5374-2839)
- Hartmuth C. Kolb (ORCID: https://orcid.org/0000-0003-2414-5792)
- Rosita Shishegar (ORCID: https://orcid.org/0000-0002-2454-3443)
- Christopher Fowler (ORCID: https://orcid.org/0000-0003-1397-0359)
- Simon M. Laws (ORCID: https://orcid.org/0000-0002-4355-7082)
- Larry D. Ward
- Ziad S. Saad
Institutions
- Edith Cowan University (AU)
- Commonwealth Scientific and Industrial Research Organisation (AU)
- The University of Melbourne (AU)
- University of Pittsburgh (US)
- Curtin University (AU)
- Florey Institute of Neuroscience and Mental Health (AU)
- Australian e-Health Research Centre (AU)
- Janssen (United States) (US)
- Austin Health (AU)
Publication Details
- Journal
- Communications Medicine
- Published
- 2025-02-27
- DOI
- https://doi.org/10.1038/s43856-025-00768-z
- Citations
- 7
- Primary Topic
- Dementia and Cognitive Impairment Research
- Type
- article
- Field-Weighted Citation Impact
- 10.30
Funders
- Australian Government
- National Health and Medical Research Council
- Janssen Pharmaceuticals